QuidelOrtho Corporation (QDEL)
Automate Your Wheel Strategy on QDEL
With Tiblio's Option Bot, you can configure your own wheel strategy including QDEL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol QDEL
- Rev/Share 40.9481
- Book/Share 44.403
- PB 0.6734
- Debt/Equity 0.1859
- CurrentRatio 1.2015
- ROIC -0.014
- MktCap 2022014410.0
- FreeCF/Share 0.4504
- PFCF 66.5136
- PE -6.0481
- Debt/Assets 0.0862
- DivYield 0
- ROE -0.1082
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | QDEL | Jefferies | Hold | Buy | -- | $44 | May 8, 2025 |
| Upgrade | QDEL | Citigroup | Neutral | Buy | $44 | $50 | Dec. 11, 2024 |
| Initiation | QDEL | Jefferies | -- | Hold | -- | $43 | Dec. 10, 2024 |
| Resumed | QDEL | UBS | -- | Neutral | $42 | $50 | Sept. 19, 2024 |
| Upgrade | QDEL | Craig Hallum | Hold | Buy | $40 | $57 | Sept. 5, 2024 |
News
Why QuidelOrtho (QDEL) is a Top Momentum Stock for the Long-Term
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Here's Why QuidelOrtho (QDEL) is a Strong Growth Stock
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
QuidelOrtho to Participate in Upcoming Investor Conferences
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will participate in two upcoming investor conferences: William Blair 45th Annual Growth Stock Conference, Wednesday, June 4, 2025 Members of QuidelOrtho's management team will participate in a presentation at 9:00 a.m. ET.
Read More
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Neutral
QDEL continues to witness growth on the back of its strong product portfolio.
Read More
Why QuidelOrtho (QDEL) is a Top Growth Stock for the Long-Term
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
QuidelOrtho: Stagnant Growth Means Best To Avoid (Rating Downgrade)
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Neutral
Despite a once promising future, QuidelOrtho Corporation's current prospects are unappealing. I rated QuidelOrtho as a "Buy" in July 2023, but the stock has since declined by ~60% as its growth has stagnated. On 05/07/2025 the company reported top and bottom-line beats for its Q1/2025 earnings, bumping its shares up >40%.
Read More
QuidelOrtho Stock Gains Following Q1 Earnings Beat, Margins Expand
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Despite solid performances by the Labs and Immunohematology units and EMEA and Other regions, QDEL reports soft overall top-line results in first-quarter 2025.
Read More
QuidelOrtho Corporation (QDEL) Q1 2025 Earnings Call Transcript
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral
QuidelOrtho Corporation (NASDAQ:QDEL ) Q1 2025 Results Conference Call May 7, 2025 5:00 PM ET Company Participants Juliet Cunningham - Vice President, Investor Relations Brian Blaser - President and Chief Executive Officer Joe Busky - Chief Financial Officer Conference Call Participants Conor McNamara - RBC Capital Patrick Donnelly - Citi Andrew Brackmann - William Blair Jack Meehan - Nephron Research Lu Li - UBS Casey Woodring - JPMorgan Andrew Cooper - Raymond James Tycho Peterson - Jefferies Operator Welcome to the QuidelOrtho First Quarter 2025 Financial Results Conference Call and Webcast. At this time, all participant lines are in listen …
Read More
QuidelOrtho (QDEL) Q1 Earnings and Revenues Top Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
QuidelOrtho (QDEL) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.58 per share. This compares to earnings of $0.44 per share a year ago.
Read More
MedTech Stocks' Earnings to Watch on May 7: COR, QDEL & INGN
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Neutral
The medical device sector saw steady sales growth in the first quarter of 2025, supported by innovation in AI, wearables, and personalized care. However, earnings gains were more modest as global tariffs, inflationary costs, and supply chain disruptions continued to pressure margins.
Read More
4 MedTech Stocks Poised to Outshine Q1 Earnings Estimates
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
MedTech companies' quarterly results are likely to reflect base business recovery on a year-over-year basis. Let's see how HIMS, GMED, QDRL and HAE are poised ahead of their earnings release.
Read More
Why QuidelOrtho (QDEL) Could Beat Earnings Estimates Again
Published: April 24, 2025 by: Zacks Investment Research
Sentiment: Positive
QuidelOrtho (QDEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
QuidelOrtho (QDEL) Surges 10.1%: Is This an Indication of Further Gains?
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Positive
QuidelOrtho (QDEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Read More
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Neutral
QDEL continues to witness growth on the back of its strong product portfolio.
Read More
QuidelOrtho Unveils Results Manager System to Streamline Testing
Published: March 14, 2025 by: Zacks Investment Research
Sentiment: Positive
QDEL introduces the Results Manager System, a powerful tool designed to streamline diagnostic data management, enhance efficiency, and improve patient care.
Read More
QuidelOrtho Stock Gains Following Q4 Earnings Beat, Margins Contract
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Despite solid performances by the Labs and Immunohematology units and China and Other regions, QDEL reports soft overall top-line results in fourth-quarter 2024.
Read More
QuidelOrtho Corporation (QDEL) Q4 2024 Earnings Call Transcript
Published: February 12, 2025 by: Seeking Alpha
Sentiment: Neutral
QuidelOrtho Corporation (NASDAQ:QDEL ) Q4 2024 Results Conference Call February 12, 2025 5:00 PM ET Company Participants Juliet Cunningham - Vice President, Investor Relations Brian Blaser - President and Chief Executive Officer Joe Busky - Chief Financial Officer Conference Call Participants Jack Meehan - Nephron Research Patrick Donnelly - Citi Bill Bonello - Craig-Hallum Lu Li - UBS Andrew Cooper - Raymond James Casey Woodring - JPMorgan Andrew Brackmann - William Blair Jose Ricardo - RBC Capital Markets Operator Welcome to the QuidelOrtho Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast. At this time, all participant …
Read More
About QuidelOrtho Corporation (QDEL)
- IPO Date 1991-02-01
- Website https://www.quidelortho.com
- Industry Medical - Instruments & Supplies
- CEO Mr. Brian J. Blaser
- Employees 6600